PMID- 20394491
OWN - NLM
STAT- MEDLINE
DCOM- 20100727
LR  - 20151119
IS  - 1471-1753 (Electronic)
IS  - 0954-6634 (Linking)
VI  - 21
IP  - 3
DP  - 2010 May
TI  - Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen 
      in paediatric patients with severe atopic dermatitis: a randomized, double-blind 
      trial.
PG  - 157-66
LID - 10.3109/09546630903410158 [doi]
AB  - BACKGROUND: Pimecrolimus and topical corticosteroids (TCS) combination therapy 
      may provide an alternative treatment for patients with severe atopic dermatitis 
      (AD), with faster clearance of disease flares, consequently reducing the duration 
      of TCS treatment. OBJECTIVE: To assess the safety profile of pimecrolimus cream 
      1% combined with fluticasone versus fluticasone alone in paediatric patients with 
      severe AD. METHODS: Patients (n = 376) were randomized to a combination of 
      pimecrolimus cream 1% with fluticasone or vehicle plus fluticasone for 4 weeks. 
      The primary outcome measure was the frequency of clinically relevant pre-defined 
      adverse events (AEs) associated with the topical use of corticosteroids in 
      patients with severe AD. RESULTS: Erythematous rash was the only AE, occurring 
      more frequently in the combination group, while there were no noticeable 
      differences in the frequency of other AEs of clinical interest between treatment 
      groups. Efficacy variables were comparable between the two groups. A trend for 
      greater time to relapse was observed for the combination of pimecrolimus cream 1% 
      with fluticasone in patients who were clear at the end of treatment, with a 
      marked improvement in facial AD. CONCLUSION: In paediatric patients with severe 
      AD the overall safety profile of pimecrolimus cream 1% combined with fluticasone 
      was similar to that of fluticasone alone.
FAU - Meurer, Michael
AU  - Meurer M
AD  - Universitatsklinikum Carl Gustav Carus Klinik und Poliklinik fur Dermatologie 
      Dresden, Dresden, Germany. meurer@rcs.urz.tu-dresden.de
FAU - Eichenfield, Lawrence F
AU  - Eichenfield LF
FAU - Ho, Vincent
AU  - Ho V
FAU - Potter, Paul C
AU  - Potter PC
FAU - Werfel, Thomas
AU  - Werfel T
FAU - Hultsch, Thomas
AU  - Hultsch T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - J Dermatolog Treat
JT  - The Journal of dermatological treatment
JID - 8918133
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Androstadienes)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Ointments)
RN  - 7KYV510875 (pimecrolimus)
RN  - CUT2W21N7U (Fluticasone)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - Administration, Topical
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Androstadienes/*therapeutic use
MH  - Dermatitis, Atopic/*diagnosis/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fluticasone
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Male
MH  - Ointments/therapeutic use
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - Tacrolimus/*analogs & derivatives/therapeutic use
MH  - Treatment Outcome
EDAT- 2010/04/17 06:00
MHDA- 2010/07/28 06:00
CRDT- 2010/04/17 06:00
PHST- 2010/04/17 06:00 [entrez]
PHST- 2010/04/17 06:00 [pubmed]
PHST- 2010/07/28 06:00 [medline]
AID - 10.3109/09546630903410158 [doi]
PST - ppublish
SO  - J Dermatolog Treat. 2010 May;21(3):157-66. doi: 10.3109/09546630903410158.